Neoantigen landscape in metastatic nasopharyngeal carcinoma

被引:26
|
作者
Lin, Mei [1 ,2 ,3 ]
Zhang, Xiao-Long [2 ]
Zou, Xiong [1 ,2 ,3 ,4 ]
You, Rui [1 ,2 ,3 ]
Yang, Qi [1 ,2 ,3 ]
Zou, Xiong [1 ,2 ,3 ,4 ]
Yu, Kai [2 ]
Liu, You-Ping [1 ,2 ,3 ]
Zou, Ru-Hai [4 ]
Hua, Yi-Jun [1 ,2 ,3 ]
Huang, Pei-Yu [1 ,2 ,3 ]
Wang, Jin [5 ]
Zhao, Qi [2 ]
Jiang, Xiao-Bing [6 ]
Tang, Jun [7 ]
Gu, Yang-Kui [8 ]
Yu, Tao [1 ,2 ,3 ]
He, Gui-Ping [1 ,2 ,3 ]
Xie, Yu-Long [1 ,2 ,3 ]
Wang, Zhi-Qiang [1 ,2 ,3 ]
Liu, Ting [1 ,2 ,3 ]
Chen, Si-Yuan [1 ,2 ,3 ]
Zuo, Zhi-Xiang [1 ,2 ]
Chen, Ming-Yuan [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[3] Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou 510060, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Dept Ultrasound, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China
[5] Sun Yat Sen Univ, Canc Ctr, Dept Musculoskeletal Oncol, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China
[6] Sun Yat Sen Univ, Canc Ctr, Dept Neurosurg, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China
[7] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, 51 Dongfeng East Rd, Guangzhou 510060, Peoples R China
[8] Sun Yat Sen Univ, Canc Ctr, Dept Minimally Invas Intervent Radiol, 51 Dongfeng East Rd, Guangzhou 510060, Peoples R China
来源
THERANOSTICS | 2021年 / 11卷 / 13期
基金
中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; neoantigens; subtype; metastasis; microenvironment; EPSTEIN-BARR-VIRUS; CONCURRENT CHEMORADIOTHERAPY; CHECKPOINT BLOCKADE; ANTITUMOR-ACTIVITY; CANCER STATISTICS; TUMOR PROGRESSION; GENOMIC ANALYSIS; SEQUENCING DATA; MULTICENTER; HETEROGENEITY;
D O I
10.7150/thno.53229
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Reportedly, nasopharyngeal carcinoma (NPC) patients with MHC I Class aberration are prone to poor survival outcomes, which indicates that the deficiency of tumor neoantigens might represent a mechanism of immune surveillance escape in NPC. Methods: To clearly delineate the landscape of neoantigens in NPC, we performed DNA and RNA sequencing on paired primary tumor, regional lymph node metastasis and distant metastasis samples from 26 patients. Neoantigens were predicted using pVACseq pipeline. Subtype prediction model was built using random forest algorithm. Results: Portraying the landscape of neoantigens in NPC for the first time, we found that the neoantigen load of NPC was above average compared to that of other cancers in The Cancer Genome Atlas program. While the quantity and quality of neoantigens were similar among primary tumor, regional lymph node metastasis and distant metastasis samples, neoantigen depletion was more severe in metastatic sites than in primary tumors. Upon tracking the clonality change of neoantigens, we found that neoantigen reduction occurred during metastasis. Building a subtype prediction model based on reported data, we observed that subtype I lacked T cells and suffered from severe neoantigen depletion, subtype II highly expressed immune checkpoint molecules and suffered from the least neoantigen depletion, and subtype III was heterogenous. Conclusions: These results indicate that neoantigens are conducive to the guidance of clinical treatment, and personalized therapeutic vaccines for NPC deserve deeper basic and clinical investigations to make them feasible in the future.
引用
收藏
页码:6427 / 6444
页数:18
相关论文
共 50 条
  • [41] Metastatic retropharyngeal lymph nodes in nasopharyngeal carcinoma: imaging criteria
    Sharma, Manas
    Bartlett, Eric
    Yu, Eugene
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (11) : 1703 - 1706
  • [42] Chemokine receptor expression in metastatic destination of nasopharyngeal carcinoma (NPC)
    Chen, CL
    Ou, DL
    Lin, LI
    Cheng, AL
    MODERN PATHOLOGY, 2005, 18 : 212A - 212A
  • [43] Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
    Sato, Hiroki
    Fushimi, Chihiro
    Okada, Takuro
    Matsuki, Takashi
    Kondo, Takahito
    Omura, G. O.
    Miura, Kouki
    Yamashita, Taku
    Okamoto, Isaku
    Tsukahara, Kiyoaki
    IN VIVO, 2020, 34 (05): : 2967 - 2972
  • [44] Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
    Shaodong Hong
    Li Zhang
    ChineseJournalofCancer, 2016, 35 (12) : 645 - 646
  • [45] Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma
    Xu, Tingting
    Ou, Xiaomin
    Shen, Chunying
    Hu, Chaosu
    ANTI-CANCER DRUGS, 2016, 27 (01) : 66 - 70
  • [46] Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
    Chan, Stephen L.
    Hui, Edwin P.
    Leung, Sing F.
    Chan, Anthony T. C.
    Ma, Brigette B. Y.
    BMC CANCER, 2006, 6 (1)
  • [47] Metastatic nasopharyngeal carcinoma mimicking nodular sclerosis Hodgkin lymphoma
    Liu, Huifei
    Audino, Anthony N.
    BLOOD, 2020, 136 (22) : 2596 - 2596
  • [48] Cetuximab plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
    Kerboua, Esma
    Lagha, Newel
    Kara, Ferdous
    Bouzid, Kamel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review
    A Prawira
    S F Oosting
    T W Chen
    K A delos Santos
    R Saluja
    L Wang
    L L Siu
    K K W Chan
    A R Hansen
    British Journal of Cancer, 2017, 117 : 1743 - 1752
  • [50] Chemokine receptor expression in metastatic destination of nasopharyngeal carcinoma (NPC)
    Chen, CL
    Ou, DL
    Lin, LI
    Cheng, AL
    LABORATORY INVESTIGATION, 2005, 85 : 212A - 212A